Lyell Immunopharma Inc.
(LYEL)
undefined
undefined%
At close: undefined
Balance Sheet (Annual)
Get detailed breakdowns of the balance-sheet with total debts,
total investments, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Cash & Equivalents | 145.65M | 123.55M | 293.83M | 140.41M | 96.67M |
| Short-Term Investments | 400.58M | 516.60M | 320.97M | 472.21M | 339.38M |
| Long-Term Investments | 48.51M | 115.04M | 330.53M | 163.44M | 68.98M |
| Other Long-Term Assets | 4.52M | 4.96M | 3.95M | 3.23M | 2.68M |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 8.46M | 11.14M | 22.98M | 4.93M | 8.42M |
| Total Current Assets | 554.69M | 651.29M | 626.29M | 617.55M | 440.26M |
| Property-Plant & Equipment | 142.32M | 166.26M | 166.64M | 124.06M | 43.70M |
| Goodwill & Intangibles | - | - | - | - | - |
| Total Long-Term Assets | 195.34M | 286.27M | 501.12M | 290.73M | 115.37M |
| Total Assets | 750.03M | 937.56M | 1.13B | 908.28M | 555.63M |
| Account Payables | 4.82M | 3.92M | 3.21M | 9.40M | 2.84M |
| Deferred Revenue | - | 21.87M | 4.99M | 6.09M | 4.51M |
| Short-Term Debt | 6.27M | 4.53M | 1.17M | 3.62M | 344.00K |
| Other Current Liabilities | 23.43M | 28.58M | 37.37M | 30.18M | 14.35M |
| Total Current Liabilities | 34.52M | 37.03M | 46.74M | 49.28M | 22.05M |
| Long-Term Debt | 56.89M | 126.34M | 133.30M | 50.96M | 27.13M |
| Other Long-Term Liabilities | 3.66M | -59.05M | -62.08M | 532.00K | - |
| Total Long-Term Liabilities | 60.56M | 67.28M | 150.88M | 140.56M | 125.53M |
| Total Liabilities | 95.08M | 104.31M | 197.62M | 189.84M | 147.58M |
| Total Debt | 63.17M | 67.70M | 67.82M | 54.57M | 27.47M |
| Common Stock | 25.00K | 25.00K | 24.00K | 2.00K | 1K |
| Retained Earnings | -1.00B | -767.48M | -584.36M | -334.14M | -129.67M |
| Comprehensive Income | -94.00K | -7.60M | -1.62M | 256.00K | 454.00K |
| Shareholders Equity | 654.95M | 833.25M | 929.79M | 718.44M | 408.06M |
| Total Investments | 449.08M | 631.64M | 651.50M | 635.66M | 408.36M |